References
- Schoenwetter WF. Allergic rhinitis: epidemiology and natural history. Allergy Asthma Proc 2000;21:1–6
- Verlato G, Corsico A, Villani S, et al. Is the prevalence of adult asthma and allergic rhinitis still increasing? Results of an Italian study. J Allergy Clin Immunol 2003;111:1232–8
- Settipane RA. Complications of allergic rhinitis. Allergy Asthma Proc 1999;20:209–13
- Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001;108(Suppl 1):S45–S53
- Thompson AK, Juniper E, Meltzer EO. Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2000; 85:338–47
- Howarth P. The choice of an H1-antihistamine for the 21st century. Clin Exp Allergy Rev 2002;2:1–8
- Druce H, Kaliner M. Allergic Rhinitis. J Am Med Assoc 1988;259:260–3
- Busse W. The role of leukotrienes in asthma and allergic rhinitis. Clin Exp Allergy 1996;26:868–79
- Flowers BK, Proud D, Kagey-Sobotka A, et al. The effect of a leukotriene antagonist on the early response to antigen. Otolaryngol Head Neck Surg 1990;102:219–24
- Juniper E, Rohrbaugh T, Meltzer E. A questionnaire to measure quality of life in adults with nocturnal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2003;111:484–90
- Johnson D, Hricik J. The pharmacology of alpha-adrenergic decongestants. Pharmacotherapy 1993;13:110S–5S
- Cantu C, Arauz A, Murillo-Bonilla L, et al. Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. Stroke 2003;34:1667–72
- Beck R, Mercado D, Seguin S, et al. Cardiovascular effects of pseudoephedrine in medically controlled hypertensive patients. Arch Intern Med 1992;152:1242–5
- Cappell M. Colonic toxicity of administered drugs and chemicals. Am J Gastroenterol 2004;99:1175–90
- Berkowitz R, McCafferty F, Lutz C, et al. Fexofenadine HCl 60 mg/pseudoephedrine HCl 120 mg has a 60-minute onset of action in the treatment of seasonal allergic rhinitis symptoms, as assessed in an allergen exposure unit. Allergy Asthma Proc 2004;25:335–43
- Berkowitz R, Woodworth G, Lutz C, et al. Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit. Ann Allergy Asthma Immunol 2002;89:38–45
- Sussman G, Mason J, Compton D, et al. The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. J Allergy Clin Immunol 1999;104:100–6
- Richter A, Anton S, Koch P, et al. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307–35
- Horak F, Toth J, Marks B, et al. Efficacy and safety relative to placebo of an oral formulation of cetirizine and sustained-release pseudoephedrine in the management of nasal congestion. Allergy 1998;53:849–56
- Schenkel E, Corren J, Murray J. Efficacy of once-daily desloratadine/ pseudoephedrine for relief of nasal congestion. Allergy Asthma Proc 2002;23:325–30
- Bronsky E, Boggs P, Findlay S, et al. Comparative efficacy and safety of a once-daily loratadine–pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. J Allergy Clin Immunol 1995;96:139–47
- Stubner U, Toth J, Marks B, et al. Efficacy and safety of an oral formulation of cetirizine and prolonged-release pseudoephedrine versus xylometazoline nasal spray in nasal congestion. Arzneimittel-Forschung 2001;51:904–10
- Hindmarch I. CNS effects of antihistamines: is there a third generation of non-sedative drugs? Clin Exp Allergy Rev 2002; 2:26–31
- Bertrand B, Jamart J, Marchal J, et al. Cetirizine and pseudoephedrine retard alone and in combination in the treatment of perennial allergic rhinitis: a double-blind multicentre study. Rhinology 1996;34:91–6
- Zyrtec-D 12 hour→ (cetirizine hydrochloride 5 mg and pseudoephedrine hydrochloride 120 mg extended release tablets product information package insert). New York, USA: Pfizer Inc; 2004
- US Department of Health and Human Services. Agency for Healthcare Research and Quality. Management of allergic and nonallergic rhinitis. Summary, Evidence Report/Technology Assessment: Number 54 (2002). Available from http://www.%20ahrq.gov/clinic/epcsums/rhinsum.htm [accessed 2005]